Pharmaceuticals

Kingdomway

Kingdomway released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 813.36 M, actual EPS CNY 0.11

Kingdomway FY2026 Q1 Earnings Release Scheduled for April 30 After-Market BJT

Kingdomway released FY2025 Q4 earnings on April 20 After-Market BJT, actual revenue CNY 761.1 M, actual EPS CNY -0.0352

Kingdomway released FY2025 Annual Earnings on April 20 After-Market (BJT), Actual Revenue: CNY 3.365 B (Forecast: CNY 3.528 B), Actual EPS: CNY 0.55 (Forecast: CNY 0.72)

Kingdomway to Release FY2025 Earnings on April 21 After-Market (BJT), Forecast Revenue CNY 3.528 B, EPS CNY 0.72

Kingdomway released FY2025 9 Months Earnings on October 24 Pre-Market BJT, actual revenue CNY 2.604 B, actual EPS CNY 0.5907

Kingdomway released FY2025 Q3 earnings on October 24 Pre-Market (BJT), actual revenue CNY 875.78 M, actual EPS CNY 0.1806

Kingdomway FY2025 Q3 Earnings Release on October 25, 2025 Pre-Market BJT

Kingdomway released FY2025 Q2 earnings on August 27 Pre-Market (BJT), actual revenue CNY 901.25M, actual EPS CNY 0.21

Kingdomway released FY2025 Semi-Annual earnings on August 27 Pre-Market BJT, actual revenue CNY 1.728 B, actual EPS CNY 0.41

Kingdomway FY2025 Semi-Annual Earning Release on August 28, 2025 (BJT)

Jindawei's Net Profit Forecast to Increase by 70%-100% in H1 2025 Due to Q10 and Vitamin A Sales Growth

Jindahui Subsidiary Receives Patent for Nattokinase Purification Method

Jindawei Secretary Discusses Vitamin D3 Sales and Impact of US-China Trade War

Jindawei's health brand selling well during 618 shopping festival

Quantum Capital Surveys Jindebiwei

Jiang Bin, Jin 达 Wei Chairman, Explains Growth Drivers and Synthetic Biology Advantages

Jindawei Explains Response Strategies to Changes in Sino-US Relations

Jindawei's Doctor's Best Launches Ergothioneine Product

JinDaWei Q1 Profits Up 72%, Jiang Bin Explains Market Cap Management

002626

Viactiv®, a brand of calcium chew supplements, has received the 2026 Women's Choice Award® based on a national survey of women consumers. Over 85% of users indicated they would recommend Viactiv Calcium Chews to others, meeting the award's criteria. The recognition highlights the brand's commitment to quality and customer satisfaction, as stated by Viactiv's CMO, Katie Lucas. The Women's Choice Award® serves as a trusted indicator of consumer recommendations among women, simplifying their decision-making process in the marketplace.

prnewswire

12:09 ETViactiv® Named 2026 Women's Choice Award® Recipient

Kingdomway and its subsidiary Xiamen Kingdomway Vitamin Co., Ltd. have obtained an invention patent issued by the National Intellectual Property Administration, with the patent name "A Continuous Preparation Device and Method for 6-Chloro-6-Oxocaproic Acid Ethyl Ester," patent number ZL202310830368.X, with a patent term of 20 years. This invention belongs to the field of organic synthesis and features mild conditions, high yield, environmental friendliness, and low cost. Although this patent does not significantly impact the company's operations, it contributes to technological innovation and enhances core competitiveness

Zhitong

Kingdomway: Subsidiary obtains invention patent for "Preparation of 6-Chloro-6-Oxocaproic Acid Ethyl Ester"

According to the Zhitong Finance APP, Kingdomway released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 2.604 billion yuan, a year-on-year increase of 11.16%. The net profit attributable to shareholders of the listed company was 361 million yuan, a year-on-year increase of 63.47%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 349 million yuan, a year-on-year increase of 56.22%

Kingdomway released its performance for the first three quarters, with a net profit attributable to the parent company of 361 million yuan, a year-on-year increase of 63.47%

According to the Zhitong Finance APP, Kingdomway announced that its holding subsidiary, Jiangsu Chengxin Pharmaceutical Co., Ltd., recently received the veterinary drug product approval number issued by the Ministry of Agriculture and Rural Affairs of the People's Republic of China. Generic name: Praziquantel, veterinary drug product approval number: Veterinary Drug Original Character 102091173

Kingdomway's subsidiary has obtained the approval number for veterinary drug products

Kingdomway announced that the company and its subsidiaries recently received an invention patent certificate issued by the National Intellectual Property Administration. The invention is titled "A Preparation Method and Preparation Device for 7-Dehydrocholesterol and Vitamin D3," with patent number ZL 2023.1 billion, and the patent rights are valid for twenty years. This invention relates to the field of organic synthesis and can effectively improve the yield and purity of 7-Dehydrocholesterol

Kingdomway: Obtained an invention patent certificate

According to the Zhitong Finance APP, Kingdomway released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 1.728 billion yuan, a year-on-year increase of 13.46%. The net profit attributable to shareholders of the listed company was 247 million yuan, a year-on-year increase of 90.12%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 241 million yuan, a year-on-year increase of 86.10%. The basic earnings per share were 0.41 yuan

Kingdomway released its performance for the first half of the year, with a net profit attributable to the parent company of 247 million yuan, a year-on-year increase of 90.12%

According to the Zhitong Finance APP, Kingdomway announced that the company plans to issue convertible bonds worth 1.292 billion yuan, totaling 12,923,948 bonds. The initial conversion price for the convertible bonds is 19.59 yuan per share. The preferential subscription date for existing shareholders and the online subscription date for this issuance of convertible bonds are both set for August 20, 2025 (T day), with the subscription time from 9:15 to 11:30 and 13:00 to 15:00 on T day

Kingdomway: The company's convertible bonds will be available for subscription starting August 20

Kingdomway's wholly-owned subsidiary has established a joint venture with Aibede to promote the application of nanocrystal production technology in products such as coenzyme Q10, enhance product absorption efficiency, strengthen market competitiveness, and support global business expansion

Kingdomway's subsidiary and Aibede jointly established a joint venture to promote the application of nanocrystal production technology

According to the Zhitong Finance APP, Kingdomway disclosed its performance forecast for the first half of 2025, with a net profit attributable to shareholders of the listed company expected to be between 221 million yuan and 260 million yuan, a year-on-year increase of 70%–100%; the net profit after deducting non-recurring gains and losses is expected to be between 220 million yuan and 259 million yuan, also a year-on-year increase of 70%–100%

Kingdomway issued a profit forecast, expecting a net profit attributable to the parent company of 221 million to 260 million yuan in the first half of the year, a year-on-year increase of 70%–100%

Kingdomway stated on the interactive platform that its American health supplement brand Doctor's Best has launched a product containing ergothioneine, which is sold in the domestic market through cross-border e-commerce platforms, such as brand flagship stores on Tmall Global and JD Worldwide

Kingdomway(002626.SZ)